IDH2 and astrocytoma (excluding glioblastoma): In one case, a newly diagnosed grade 4 IDH-mutant astrocytoma was positive for MGMT promoter methylation on pyrosequencing (35.9% CpG site methylation), but the recurrent tumor 8 months later was negative on pyrosequencing (5.4%).